4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing
4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing
Read moreFri, 28th Sep 2018 08:29
4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing
Read more(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.
Read more4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial
Read more(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.
Read more4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study
Read more4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs
Read more4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment
Read more(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.
Read more4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug
Read more(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.
Read more4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data
Read moreDIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares
Read moreUPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription
Read more(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.
Read more4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies
Read more